A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa.

Adolescents Conjoint analysis Discrete choice experiment (DCE) HIV Oral pre-exposure prophylaxis (PrEP) Preferences South Africa Young people

Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 06 07 2020
accepted: 19 11 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 28 4 2021
Statut: epublish

Résumé

The uptake and adherence of daily oral PrEP has been poor in high-risk populations in South Africa including young people. We used qualitative research methods to explore user preferences for daily and on-demand oral PrEP use among young South Africans, and to inform the identification of critical attributes and attribute-levels for quantitative analysis of user preferences, i.e. a discrete choice experiment (DCE). Data were collected between September and November 2018 from eight group discussions and 20 in-depth interviews with young people 13 to 24 years in Cape Town and Johannesburg. Using a convenience sampling strategy, participants were stratified by sex and age. Interviewers used a semi-structured interview guide to discuss several attributes (dosing regimen, location, costs, side effects, and protection period) for PrEP access and use. Group discussions and in-depth interviews were audio-recorded, transcribed verbatim and translated to English. We used framework analysis to explore context-specific attributes and attribute-levels for delivering oral PrEP in South Africa. The adolescent community advisory board, expert and study team opinions were consulted for the final DCE attributes and levels. We enrolled 74 participants who were 51% (n = 38/74) male, had a median age of 18.5 [Interquartile range = 16-21.25] years, 91% (n = 67/74) identified as heterosexual and 49% (n = 36/74) had not completed 12th grade education. Using the qualitative data, we identified five candidate attributes including (1) dosing regimen, (2) location to get PrEP, (3) cost, (4) route of administration and (5) frequency. After discussions with experts and the study team, we revised the DCE to include the following five attributes and levels: dosing regime: daily, and on-demand PrEP; location: private pharmacy, public clinic, mobile clinic, ATM); cost: free-of-charge, R50 (~2GBP), R265 (~12GBP); side effects: nausea, headache, rash; and duration of protection: fulltime protection versus when PrEP is used). There is limited literature on qualitative research methods describing the step-by-step process of developing a DCE for PrEP in adolescents, especially in resource-constrained countries. We provide the process followed for the DCE technique to understand user preferences for daily and on-demand oral PrEP among young people in South Africa.

Sections du résumé

BACKGROUND BACKGROUND
The uptake and adherence of daily oral PrEP has been poor in high-risk populations in South Africa including young people. We used qualitative research methods to explore user preferences for daily and on-demand oral PrEP use among young South Africans, and to inform the identification of critical attributes and attribute-levels for quantitative analysis of user preferences, i.e. a discrete choice experiment (DCE).
METHODS METHODS
Data were collected between September and November 2018 from eight group discussions and 20 in-depth interviews with young people 13 to 24 years in Cape Town and Johannesburg. Using a convenience sampling strategy, participants were stratified by sex and age. Interviewers used a semi-structured interview guide to discuss several attributes (dosing regimen, location, costs, side effects, and protection period) for PrEP access and use. Group discussions and in-depth interviews were audio-recorded, transcribed verbatim and translated to English. We used framework analysis to explore context-specific attributes and attribute-levels for delivering oral PrEP in South Africa. The adolescent community advisory board, expert and study team opinions were consulted for the final DCE attributes and levels.
RESULTS RESULTS
We enrolled 74 participants who were 51% (n = 38/74) male, had a median age of 18.5 [Interquartile range = 16-21.25] years, 91% (n = 67/74) identified as heterosexual and 49% (n = 36/74) had not completed 12th grade education. Using the qualitative data, we identified five candidate attributes including (1) dosing regimen, (2) location to get PrEP, (3) cost, (4) route of administration and (5) frequency. After discussions with experts and the study team, we revised the DCE to include the following five attributes and levels: dosing regime: daily, and on-demand PrEP; location: private pharmacy, public clinic, mobile clinic, ATM); cost: free-of-charge, R50 (~2GBP), R265 (~12GBP); side effects: nausea, headache, rash; and duration of protection: fulltime protection versus when PrEP is used).
CONCLUSIONS CONCLUSIONS
There is limited literature on qualitative research methods describing the step-by-step process of developing a DCE for PrEP in adolescents, especially in resource-constrained countries. We provide the process followed for the DCE technique to understand user preferences for daily and on-demand oral PrEP among young people in South Africa.

Identifiants

pubmed: 33407395
doi: 10.1186/s12913-020-05942-8
pii: 10.1186/s12913-020-05942-8
pmc: PMC7788832
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Subventions

Organisme : European and Developing Countries Clinical Trials Partnership
ID : RIA2016MC-1616 CHAPS
Organisme : International AIDS Society
ID : CIPHER: Growing the leaders fellowship

Références

PLoS One. 2013 Dec 30;8(12):e83193
pubmed: 24386160
Medicine (Baltimore). 2019 Oct;98(43):e17716
pubmed: 31651904
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
BMC Health Serv Res. 2014 May 22;14:235
pubmed: 24884920
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Health Technol Assess. 2015 Nov;19(94):1-176
pubmed: 26562004
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Trials. 2020 Oct 30;21(1):900
pubmed: 33121503
BMC Health Serv Res. 2019 Mar 28;19(1):195
pubmed: 30922372
Health Policy Plan. 2009 Mar;24(2):151-8
pubmed: 19112071
Infect Dis Ther. 2017 Sep;6(3):363-382
pubmed: 28600755
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Soc Sci Med. 2016 Mar;153:1-11
pubmed: 26859436
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Clin Investig (Lond). 2013 Mar;3(3):
pubmed: 24409341
J Infect Dis. 2013 Jul 15;208(2):189-91
pubmed: 23570851
AIDS Behav. 2020 May;24(5):1294-1303
pubmed: 31720955
Med Decis Making. 2018 Jan;38(1):120-133
pubmed: 28863752
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
AIDS Care. 2019 May;31(5):545-553
pubmed: 30554519
AIDS Behav. 2017 Sep;21(9):2579-2588
pubmed: 28058565
SAHARA J. 2004 Nov;1(3):157-64
pubmed: 17601003
J Int AIDS Soc. 2020 Jun;23(6):e25528
pubmed: 32544303
Qual Health Care. 2001 Sep;10 Suppl 1:i55-60
pubmed: 11533440
J Adolesc Health. 2017 May;60(5):487-512
pubmed: 28087268
Health Econ. 2012 Feb;21(2):145-72
pubmed: 22223558
PLoS One. 2019 Mar 27;14(3):e0210719
pubmed: 30917121
Reprod Health Matters. 2006 May;14(27):109-18
pubmed: 16713885
AIDS. 2013 Aug 24;27(13):2155-60
pubmed: 24384592
J Health Serv Res Policy. 2007 Jan;12(1):25-30
pubmed: 17244394
PLoS One. 2012;7(1):e28238
pubmed: 22247757
Drugs. 2019 Aug;79(12):1263-1276
pubmed: 31309457
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
AIDS Behav. 2014 Sep;18(9):1701-11
pubmed: 24871870
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Int J STD AIDS. 2011 May;22(5):256-62
pubmed: 21571973
Science. 2010 Sep 3;329(5996):1168-74
pubmed: 20643915
Lancet HIV. 2018 Feb;5(2):e68-e78
pubmed: 28986029
BMC Public Health. 2020 Nov 7;20(1):1669
pubmed: 33160341
Youth Soc. 2014 Jul 1;46(4):529-547
pubmed: 25328252

Auteurs

Janan J Dietrich (JJ)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. dietrichj@phru.co.za.
Health Systems Research Unit, South African Medical Research Council, Bellville, South Africa. dietrichj@phru.co.za.

Millicent Atujuna (M)

Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Gugulethu Tshabalala (G)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Stefanie Hornschuh (S)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Mamakiri Mulaudzi (M)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Michelle Koh (M)

Harvard Global Health Institute, Harvard University, Cambridge, MA, USA.

Nadia Ahmed (N)

Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Mortimer Market Centre, Central North West London NHS Trust, Off Caper Street, London, WC1E 6 JB, UK.

Richard Muhumuza (R)

Medical Research Council/Uganda Virus Research Institute , Entebbe, Uganda.
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

Andrew S Ssemata (AS)

Medical Research Council/Uganda Virus Research Institute , Entebbe, Uganda.
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

Kennedy Otwombe (K)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Linda-Gail Bekker (LG)

Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Janet Seeley (J)

Medical Research Council/Uganda Virus Research Institute , Entebbe, Uganda.
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

Neil A Martinson (NA)

Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Fern Terris-Prestholt (F)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

Julie Fox (J)

King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH